Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04114877 · ClinicalTrials.gov registry record · NA

Perinatal Attentional Retraining Intervention for Smoking for Minority Women

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT04114877: Completed NA study, sponsored by Yale University.

NCT04114877 is a NA study that has completed, run by Yale University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04114877, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

The proposed research intends to randomize 50 abstinent pregnant Black or Hispanic smokers to receive either the attentional retraining (AR) or control VP task. Participants will be asked to carry around a smartphone as they go about their daily lives for 2 weeks in their last month of pregnancy (Phase 1). The smartphone will sound an alert randomly during the day, at which time participants will be asked to respond to a short set of questions assessing subjective states; this will be followed by a request to complete the AR (or control) procedures. This same procedure will be repeated for 2 weeks immediately after delivery (Phase 2). Women will undergo a follow-up visit 3 months after the end of Phase 2, and complete an unmodified VP and follow-up assessments.

Primary Outcome

Attentional bias (AB) is assessed using the standard (unmodified) visual probe (VP) task on the smartphone and study visits, and measured by the reaction time (RT) in milliseconds, i.e. the time it takes a participant to identify the location of the probe after presentation of the stimulus. The AB scores will be computed as the difference in RTs on trials where the probe replaced the smoking picture vs. trials where the probe replaced the neutral picture. The VP task can measure attentional bias

Interventions

  • BEHAVIORAL Attentional retraining (AR)
  • BEHAVIORAL Visual probe (VP)

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2020-11-18
Est. Completion 2023-12-01
Phase NA
Yale University

1,492 total trials

What the finished NCT04114877 record still lists

NCT04114877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Attentional retraining (AR) is the first listed.

NCT04114877 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04114877 about?

NCT04114877 is a clinical study titled "Perinatal Attentional Retraining Intervention for Smoking for Minority Women". The proposed research intends to randomize 50 abstinent pregnant Black or Hispanic smokers to receive either the attentional retraining (AR) or control VP task. Participants will be asked to carry around a smartphone as they go about their daily lives for 2 weeks in their last month of pregnancy (Ph...

What is the current status of trial NCT04114877?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2020-11-18. Estimated completion is 2023-12-01.

What interventions are being tested in trial NCT04114877?

The interventions under investigation include: Attentional retraining (AR) (BEHAVIORAL), Visual probe (VP) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04114877?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04114877's enrollment target sits among peer trials

22 1756th of 2000 higher than 239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04114877, the US trial registry maintained by the National Library of Medicine. NCT04114877 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.